Blog

The EG.5 substrain of the Omicron variant of COVID-19 has become the most prominent source of coronavirus infections in China, the Chinese Center for Disease Control and Prevention said on Saturday.

Recently, another traditional Chinese medicine (TCM) compound preparation Pipa Qingfei granules regulated as one of the ancient classic formulae (which is a category 3.1 innovative TCM) is approved for marketing through technical evaluation. The formula of this TCM is derived from the Yi Zong Jin Jian (Golden Mirror of Medicine) by Wu Qian etc. from Qing dynasty, and enlisted in the Directory of Ancient Classic Formulae of Traditional Chinese Medicine (the first directory). The marketing authorization holder of this TCM is Jilin Aodong Taonan Pharmaceutical Co., Ltd.

Recently, the new traditional Chinese medicine (TCM) compound preparation Qijiao Tiaojing Granule of Hunan Anbang Pharmaceutical Co., Ltd. was approved for marketing by China NMPA.

Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenge Bushen Capsule of Xinjiang Huachun Biological Pharmaceutical Co., Ltd was approved for marketing by China NMPA.

Recently, the innovative product Single-port Laparoscope Surgery System of Beijing Surgerii Robotics Company Limited is approved by China NMPA.

To further standardize the regulation on labels of prepared slices of Chinese crude drugs, in accordance with laws, administrative regulations and provisions including the Drug Administration Law of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China and the Provisions for Drug Insert Sheets and Labels, the NMPA organized to formulate the Rules for Labels of Prepared Slices of Chinese Crude Drugs, which is hereby released and shall be implemented since August 1, 2024. The labeling of expiration date according to the Rules shall be implemented since August 1, 2025.